Neocyte

Chemotherapy-induced neutropenia.

IV/SC Patient on low dose chemotherapy or w/ nonserious marrow depression damage 1.25 mcg/kg/day. Patient w/ high intensity chemotherapy or obvious decline of granulocytes 2.5 mcg/kg/day for 7 days. Patient w/ neutrophilic granulocytes <1 x 10⁹/L 5 mcg/kg/day.

Hypersensitivity to filgrastim, E. coli-derived proteins. Increased dose of cytotoxic chemotherapy beyond established dosage regimens. Severe congenital neutropenia (Kostmann's syndrome) w/ abnormal cytogenetics.

Splenic rupture, severe sick cell crisis. Do not administer 24 hr before to 24 hr after cytotoxic chemotherapy. Avoid simultaneous use w/ chemotherapy & RT. Chronic myeloid leukemia & myelodysplasia. Cardiac events (MI, arrhythmias). Closely monitor patients w/ preexisting cardiac conditions. Response may be diminished in patients w/ reduced neutrophil precursors eg, previously treated w/ extensive dose of chemotherapy or RT. Regular monitoring of hematocrit & platelet count; CBC 2 times a wk during therapy in order to avoid potential complications of excessive leukocytosis. Allergic reactions eg, rash, urticarial, facial edema, wheezing, dyspnea, hypotension & tachycardia. Cutaneous vasculitis, immunogenicity, acute resp distress syndrome. Evaluate patients on therapy who develop fever, lung infiltrates or resp distress for possibility of acute resp distress syndrome. Increased doses of chemotherapy. Diagnosis of congenital, cyclic or idiopathic neutropenia, which may be difficult to distinguish from myelodysplasia, before initiating therapy. Osteoporosis. Monitor patients w/ severe chronic neutropenia, particularly w/ congenital neutropenia & underlying osteoporotic bone disease for possible occurrence of bone density changes while on long-term therapy. Infections causing myelosuppression. Pregnancy & lactation. Childn <18 yr.

Nausea, vomiting, abdominal pain; thrombocytopenia, anemia; increased γ-glutamyl transpeptidase, alkaline phosphatase, LDH & uric acid; decreased glucose & hyperuricemia; bone pain, myalgia. Mucosal inflammation, constipation, diarrhea; hepatomegaly; headache, anorexia; chest pain, musculoskeletal pain, osteoporosis; cough, pharyngolaryngeal pain; alopecia, skin rash; erythema, swelling or pruritus; fatigue, generalized weakness.

Lithium may potentiate the release of neutrophils.

Haematopoietic Agents / Supportive Care Therapy

L03AA02 - filgrastim ; Belongs to the class of colony stimulating factors. Used as immunostimulants.

Rx